The current financial score of Anavex Life Sciences Corp is 6.91. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Anavex Life Sciences Corp is 7.99. Its current P/E ratio is -5.21, which is -3.31% below the recent high of -5.03 and -368.20% above the recent low of -24.38.
The current earnings forecast score of Anavex Life Sciences Corp is 8.00. The average price target is 20.00, with a high of 20.00 and a low of 20.00.
The current price momentum score of Anavex Life Sciences Corp is 6.67. Currently, the stock price is trading between the resistance level at 3.30 and the support level at 1.93, making it suitable for range-bound swing trading.
The current institutional shareholding score of Anavex Life Sciences Corp is 3.00. The latest institutional shareholding proportion is 40.25%, representing a quarter-over-quarter decrease of 4.01%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
No risk assessment score is currently available for Anavex Life Sciences Corp. The Biotechnology & Medical Research industry's average is 3.98. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.